Core Insights - Ocumetics Technology Corp. has successfully completed key clinical milestones and is preparing for first-in-human surgeries of its innovative accommodating intraocular lens [1][2] - The company has made significant clinical progress, including site initiation, ethics committee approval, and patient recruitment for the clinical study in Mexico City [4][6] Financial Activities - Ocumetics has opted not to proceed with the second tranche of a private placement due to the imminent FIH surgeries, having successfully raised $1,124,362 in the first tranche [3] - The company incurred fees of $68,610 and issued 196,029 agent's warrants to Numus Capital Corp. for assistance with the financing [3] Clinical Progress - Key milestones include the completion of clinical study protocol training, receipt of ethics committee approval, and commencement of patient recruitment [4] - The first-in-human implantation of the accommodating intraocular lens is anticipated shortly, with ongoing monitoring of patient progress [4][6] - Planning for Group 2 surgeries is expected to take place in Q1 2026 [4]

Calgary, Alberta – TheNewswire - August 5, 2025 - Ocumetics Technology Corp. ("Ocumetics" or the "Company") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce the commencement of patient recruitment for its highly anticipated first-in-human ("FIH") study of the Ocumetics accommodating intraocular lens (the "Ocumetics Lens"). Patient recruitment is expected to be completed in approximately 7days. "We are thrilled to begin recruiting patients for this hi ...

Core Insights - Ocumetics Technology Corp. has received verbal approval from the ethics committee for its first in-human study of the Ocumetics accommodating intraocular lens, with formal written approval expected by August 5, 2025 [1][2] Group 1: Clinical Study Approval - The ethics committee's approval is a significant milestone in Ocumetics' 18-year journey to innovate vision care, allowing the company to proceed with the first clinical use of the Ocumetics Lens [2] - The approved clinical study protocol includes clinical procedures, safety monitoring, inclusion and exclusion criteria, and study endpoints, ensuring compliance with international standards for patient safety and scientific integrity [2] Group 2: Collaboration and Development - The study will be conducted in collaboration with a recognized regulatory consulting group that contributed to the protocol development and submission to regulatory agencies [3] - The approval reflects the strength of the study protocol and the readiness of the clinical team, marking a major advancement in intraocular lens development [4] Group 3: Product Overview - Ocumetics has developed an innovative intraocular lens designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses [5] - The lens allows the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses [5]